Palo Alto shares rise on earnings beat, surprising investors who worried about a Friday report

Earnings

In this article

Arora Nikesh, Palo Alto Networks CEO & Chairman at the WEF in Davos, Switzerland on May 23rd, 2022.
Adam Galica | CNBC

Palo Alto Networks shares jumped as much as 9% in extended trading on Friday after the security software vendor reported earnings that exceeded analysts’ estimates.

The stock had dropped 16% in August leading up the report as investors worried that the company’s decision to announce results late on a Friday suggested the release may include troublesome numbers.

Here’s how the company did for the quarter ended July 31:

  • Earnings: $1.44 per share, adjusted, vs. $1.28 per share, adjusted, as expected by Refinitiv.
  • Revenue: $1.95 billion, vs. $1.96 billion as expected by Refinitiv.

Revenue in its fiscal fourth quarter increased 26% from $1.6 billion a year earlier, Palo Alto said. Net income climbed to $227.7 million, or 74 cents a share, from $3.3 million, or a penny a share, a year ago.

For the first quarter, Palo Alto expects revenue of $1.82 billion to $1.85 billion, and sales for the year are expected to be $8.15 billion to $8.2 billion. That’s below analyst expectations of $1.93 billion for the fiscal first quarter and $8.38 billion for the full year, according to Refinitiv.

Palo Alto announced its earnings date on Aug. 2. West coast tech companies typically report earnings no later in the week than Thursday afternoon, giving investors an opportunity to process the numbers and trade the stock based on those results before the end of the week. Historically, companies with bad news often bury the numbers after the close of trading on Friday.

Articles You May Like

10-year Treasury yield back above 4.6% after mixed jobless claims data
CFPB takes aim at ‘bait-and-switch’ credit card rewards — consumers forfeit about $500 million worth each year
What a government shutdown could mean for air travel
GOP Budget Squabble Puts The Older Americans Act At Risk
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea, expanding use in U.S.

Leave a Reply

Your email address will not be published. Required fields are marked *